David Rimm, MD, PhD, FCAP, explains how pathologists can better distinguish IHC 1+/2+ from 0. "I'll be presenting a poster discussion on low HER2," said Dr. Rimm. "The title is 'Are We Splitting HERs?' -- a pun on hairs. But splitting is because the new drugs, the ADC [antibody-drug conjugate] trastuzumab deruxtecan [Enhertu], is indicated for patients that have HER2 1+ or 2+ IHC, but not HER2 0. And the question is, can we split those?"
For the full article click here: How to Better Identify HER2-Low Breast Cancer